[Phenotypic genetic regulation and treatment of malignant lymphoma].
Shanqi
S
Guo
Haifeng
H
Zhao
Email: yizhuozhang111@163.com.
Yizhuo
Y
Zhang
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000071221:Enhancer of Zeste Homolog 2 Protein; D044127:Epigenesis, Genetic; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D008223:Lymphoma / Q000145:classification / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D035683:MicroRNAs / Q000378:metabolism; D000077767:Panobinostat; D010641:Phenotype; D063151:Polycomb Repressive Complex 2 / Q000378:metabolism; D063146:Polycomb-Group Proteins / Q000378:metabolism*; D000077337:Vorinostat
D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007211:Indoles; D035683:MicroRNAs; D063146:Polycomb-Group Proteins; D000077337:Vorinostat; D000077767:Panobinostat; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2